- Home
- NUWE vs XRTX Comparison
NUWE vs XRTX Comparison
Compare NUWE & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUWE
- XRTX
- Stock Information
- Founded
- NUWE 1999
- XRTX 2011
- Country
- NUWE United States
- XRTX Canada
- Employees
- NUWE N/A
- XRTX N/A
- Industry
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- XRTX Pharmaceuticals and Biotechnology
- Sector
- NUWE Health Care
- XRTX Health Care
- Exchange
- NUWE Nasdaq
- XRTX Nasdaq
- Market Cap
- NUWE 3.9M
- XRTX 3.4M
- IPO Year
- NUWE N/A
- XRTX N/A
- Fundamental
- Price
- NUWE $6.88
- XRTX $0.96
- Analyst Decision
- NUWE Strong Buy
- XRTX
- Analyst Count
- NUWE 1
- XRTX 0
- Target Price
- NUWE $714.00
- XRTX N/A
- AVG Volume (30 Days)
- NUWE 121.9K
- XRTX 224.7K
- Earning Date
- NUWE 08-12-2025
- XRTX 08-13-2025
- Dividend Yield
- NUWE N/A
- XRTX N/A
- EPS Growth
- NUWE N/A
- XRTX N/A
- EPS
- NUWE N/A
- XRTX N/A
- Revenue
- NUWE $8,787,000.00
- XRTX N/A
- Revenue This Year
- NUWE $6.53
- XRTX N/A
- Revenue Next Year
- NUWE $51.63
- XRTX N/A
- P/E Ratio
- NUWE N/A
- XRTX N/A
- Revenue Growth
- NUWE N/A
- XRTX N/A
- 52 Week Low
- NUWE $6.73
- XRTX $0.80
- 52 Week High
- NUWE $197.40
- XRTX $2.98
- Technical
- Relative Strength Index (RSI)
- NUWE 25.34
- XRTX 54.93
- Support Level
- NUWE $7.20
- XRTX $0.81
- Resistance Level
- NUWE $10.08
- XRTX $0.93
- Average True Range (ATR)
- NUWE 0.99
- XRTX 0.08
- MACD
- NUWE 0.64
- XRTX 0.01
- Stochastic Oscillator
- NUWE 10.66
- XRTX 68.20
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.